This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2004 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by:
Shahid Beheshti University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00370201
First received: August 30, 2006
Last updated: October 6, 2006
Last verified: March 2004
  Purpose
This clinical trial will test the efficacy and safety of oral colchicine in prevention of proliferative vitreoretinopathy (PVR) in cases of rhegmatogenous retinal detachment

Condition Intervention Phase
Rhegmatogenous Retinal Detachment Drug: colchicine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Shahid Beheshti University of Medical Sciences:

Primary Outcome Measures:
  • proliferative vitreoretinopathy
  • retinal reattachment rate

Secondary Outcome Measures:
  • visual acuity
  • reoperation
  • macular pucker

Study Start Date: March 2004
Estimated Study Completion Date: August 2006
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Rhegmatogenous retinal detachment

Exclusion Criteria:

  • PVR grade C
  • Duration of retinal detachment ≥ one month
  • History of cataract surgery
  • History of RD surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370201

Locations
Iran, Islamic Republic of
Hamid Ahmadieh,MD
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Investigators
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
  More Information

ClinicalTrials.gov Identifier: NCT00370201     History of Changes
Other Study ID Numbers: 8259
Study First Received: August 30, 2006
Last Updated: October 6, 2006

Keywords provided by Shahid Beheshti University of Medical Sciences:
retinal detachment
proliferative vitreoretinopathy

Additional relevant MeSH terms:
Retinal Detachment
Vitreoretinopathy, Proliferative
Retinal Diseases
Eye Diseases
Colchicine
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 17, 2017